Positive Outlook on Roivant Sciences: Buy Rating Justified by Strong Cash Position and Promising Pipeline Developments
Leerink Partners analyst David Risinger has reiterated their bullish stance on ROIV stock, giving a Buy rating yesterday. David Risinger has ...
FiercePharma23h
BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Seeking Alpha1d
Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)
In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the ...
dermatologyadvisor2d
FDA Extends Review of Tapinarof Cream for Atopic Dermatitis
The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.
Roivant Sciences (ROIV) Receives a Buy from TD Cowen
TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares ...